vs
LendingClub Corp（LC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
LendingClub Corp的季度营收约是Orthofix Medical Inc.的1.1倍（$252.3M vs $219.9M），LendingClub Corp净利率更高（20.5% vs -1.0%，领先21.5%），LendingClub Corp同比增速更快（15.9% vs 2.0%），过去两年LendingClub Corp的营收复合增速更高（16.1% vs 8.0%）
LendingClub Corp是总部位于美国加利福尼亚州旧金山的金融服务企业，是全球首家将旗下产品作为证券完成注册的P2P借贷平台，同时支持贷款在二级市场交易。巅峰时期它是全球规模最大的P2P借贷平台，截至2015年12月31日，平台累计促成贷款发放额达159.8亿美元。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
LC vs OFIX — 直观对比
营收规模更大
LC
是对方的1.1倍
$219.9M
营收增速更快
LC
高出13.9%
2.0%
净利率更高
LC
高出21.5%
-1.0%
两年增速更快
LC
近两年复合增速
8.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $252.3M | $219.9M |
| 净利润 | $51.6M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 20.5% | -1.0% |
| 营收同比 | 15.9% | 2.0% |
| 净利润同比 | 341.0% | 92.4% |
| 每股收益（稀释后） | $0.44 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LCOFIX
| Q1 26 | $252.3M | — | ||
| Q4 25 | $266.5M | $219.9M | ||
| Q3 25 | $266.2M | $205.6M | ||
| Q2 25 | $248.4M | $203.1M | ||
| Q1 25 | $217.7M | $193.6M | ||
| Q4 24 | $217.2M | $215.7M | ||
| Q3 24 | $201.9M | $196.6M | ||
| Q2 24 | $187.2M | $198.6M |
净利润LCOFIX
| Q1 26 | $51.6M | — | ||
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $44.3M | $-22.8M | ||
| Q2 25 | $38.2M | $-14.1M | ||
| Q1 25 | $11.7M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $14.5M | $-27.4M | ||
| Q2 24 | $14.9M | $-33.4M |
毛利率LCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率LCOFIX
| Q1 26 | — | — | ||
| Q4 25 | 18.8% | 0.2% | ||
| Q3 25 | 21.5% | -8.3% | ||
| Q2 25 | 21.7% | -7.9% | ||
| Q1 25 | 7.2% | -25.2% | ||
| Q4 24 | 5.1% | -5.3% | ||
| Q3 24 | 8.9% | -9.6% | ||
| Q2 24 | 10.4% | -12.5% |
净利率LCOFIX
| Q1 26 | 20.5% | — | ||
| Q4 25 | — | -1.0% | ||
| Q3 25 | 16.6% | -11.1% | ||
| Q2 25 | 15.4% | -6.9% | ||
| Q1 25 | 5.4% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | 7.2% | -13.9% | ||
| Q2 24 | 8.0% | -16.8% |
每股收益（稀释后）LCOFIX
| Q1 26 | $0.44 | — | ||
| Q4 25 | $0.36 | $-0.05 | ||
| Q3 25 | $0.37 | $-0.57 | ||
| Q2 25 | $0.33 | $-0.36 | ||
| Q1 25 | $0.10 | $-1.35 | ||
| Q4 24 | $0.08 | $-0.76 | ||
| Q3 24 | $0.13 | $-0.71 | ||
| Q2 24 | $0.13 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.5B | $450.0M |
| 总资产 | $11.9B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M |
总债务LCOFIX
| Q1 26 | — | — | ||
| Q4 25 | $0 | — | ||
| Q3 25 | $0 | $157.2M | ||
| Q2 25 | $0 | $157.0M | ||
| Q1 25 | $0 | $156.9M | ||
| Q4 24 | $0 | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益LCOFIX
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.5B | $450.0M | ||
| Q3 25 | $1.5B | $442.5M | ||
| Q2 25 | $1.4B | $458.3M | ||
| Q1 25 | $1.4B | $458.3M | ||
| Q4 24 | $1.3B | $503.1M | ||
| Q3 24 | $1.3B | $525.9M | ||
| Q2 24 | $1.3B | $546.0M |
总资产LCOFIX
| Q1 26 | $11.9B | — | ||
| Q4 25 | $11.6B | $850.6M | ||
| Q3 25 | $11.1B | $832.6M | ||
| Q2 25 | $10.8B | $837.2M | ||
| Q1 25 | $10.5B | $823.1M | ||
| Q4 24 | $10.6B | $893.3M | ||
| Q3 24 | $11.0B | $867.9M | ||
| Q2 24 | $9.6B | $882.0M |
负债/权益比LCOFIX
| Q1 26 | — | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | 0.36× | ||
| Q2 25 | 0.00× | 0.34× | ||
| Q1 25 | 0.00× | 0.34× | ||
| Q4 24 | 0.00× | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流LCOFIX
| Q1 26 | — | — | ||
| Q4 25 | $-2.7B | $27.7M | ||
| Q3 25 | $-770.8M | $12.4M | ||
| Q2 25 | $-713.1M | $11.6M | ||
| Q1 25 | $-339.3M | $-18.4M | ||
| Q4 24 | $-2.6B | $23.7M | ||
| Q3 24 | $-669.8M | $11.7M | ||
| Q2 24 | $-932.5M | $9.0M |
自由现金流LCOFIX
| Q1 26 | — | — | ||
| Q4 25 | $-2.9B | $16.8M | ||
| Q3 25 | $-791.8M | $2.5M | ||
| Q2 25 | $-803.8M | $4.5M | ||
| Q1 25 | $-352.3M | $-25.1M | ||
| Q4 24 | $-2.7B | $15.2M | ||
| Q3 24 | $-682.3M | $6.3M | ||
| Q2 24 | $-945.3M | $-360.0K |
自由现金流率LCOFIX
| Q1 26 | — | — | ||
| Q4 25 | -1076.0% | 7.6% | ||
| Q3 25 | -297.4% | 1.2% | ||
| Q2 25 | -323.5% | 2.2% | ||
| Q1 25 | -161.8% | -13.0% | ||
| Q4 24 | -1237.8% | 7.0% | ||
| Q3 24 | -338.0% | 3.2% | ||
| Q2 24 | -504.9% | -0.2% |
资本支出强度LCOFIX
| Q1 26 | — | — | ||
| Q4 25 | 52.7% | 4.9% | ||
| Q3 25 | 7.9% | 4.8% | ||
| Q2 25 | 36.5% | 3.5% | ||
| Q1 25 | 6.0% | 3.5% | ||
| Q4 24 | 25.0% | 4.0% | ||
| Q3 24 | 6.2% | 2.7% | ||
| Q2 24 | 6.9% | 4.7% |
现金转化率LCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -17.41× | — | ||
| Q2 25 | -18.68× | — | ||
| Q1 25 | -29.07× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -46.33× | — | ||
| Q2 24 | -62.57× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LC
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
